Although conclusive data on the benefits of adjuvant therapy in patients with stage II/III rectal cancer are lacking, the panel recommends its use. Choice of regimen depends on initial clinical staging and predicted CRM status, with FOLFOX or CAPEOX as preferred or only options for higher risk patients and 5-FU/LV or capecitabine as additional options in some cases.